SPRY DEADLINE: Levi & Korsinsky Reminds ARS Pharmaceuticals Inc. Investors of Upcoming Securities Class Action Deadline

ARS Pharmaceuticals shares fell $2.52, or 23.9%, to $8.02 on June 25 after the company disclosed that neffy received no new commercial formulary additions in the July 1 cycle and CVS Caremark deferred its coverage decision until January 2027. A securities class action alleges ARS overstated progress toward removing prior-authorization barriers, a key commercial catalyst given that only about 57% of covered lives could access neffy without prior authorization and roughly 55% of PA submissions were approved. The delayed CVS decision leaves ARS without anticipated expanded access through the summer and back-to-school periods, posing a material near-term risk to neffy's uptake.

Analysis

The litigation notice is not a new operating datapoint and should not independently alter valuation; the relevant issue is that SPRY’s near-term revenue curve is now constrained by prescription abandonment and reimbursement friction rather than demand generation. The cash-pay bridge may preserve some unit volume, but it shifts mix toward lower-quality, potentially less durable revenue and raises questions around gross-to-net, patient persistence, and sales-force efficiency. With the key access decision deferred, the next 1-3 months lack a clean upside catalyst absent interim PBM wins, materially better-than-expected cash conversion, or evidence that retail conversion offsets lost adjudicated claims.

The more consequential second-order risk is commercial execution: a prolonged access gap can make allergists, emergency physicians, and pharmacies less willing to change established prescribing workflows, increasing the cost and time required to recapture momentum even if formulary access improves later. CVS has negligible direct earnings exposure; its relevance is as a gatekeeper whose decision could become a read-through for other PBMs' willingness to reimburse premium alternatives. Consensus may overreact to the lawsuit headline after the prior repricing, but a fundamental long requires verification that paid prescriptions, refill behavior, and net revenue per script have not deteriorated through the back-to-school period. The thesis is falsified negatively by another guidance reset or evidence that cash-pay utilization is cannibalizing reimbursed prescriptions; it is falsified positively by measurable access expansion before January or prescription growth that holds despite unchanged access.

Key Decisions for Investors

• Do not initiate a directional position solely on the class-action announcement; these notices are routine follow-on events and introduce no independently verified change to SPRY earnings power.
• Maintain an underweight or tactical short bias in SPRY over the next 1-3 months only if post-period prescription data and management commentary show decelerating paid-script growth or rising gross-to-net. Cover on evidence of a material non-CVS access win or sustained script growth without incremental discounting.
• Set a January 2027 event-driven alert rather than pre-positioning aggressively: long SPRY is actionable only if formulary access is confirmed and management quantifies the resulting lift in approval rates, net revenue per prescription, and 2027 revenue guidance. Without those metrics, access headlines alone may not justify multiple expansion.
• Avoid using CVS as a hedge or sympathy short/long; the financial exposure is immaterial relative to CVS’s diversified earnings base. Monitor CVS formulary communications only as a binary catalyst for SPRY.